Vaccine-induced humoral response of BNT162b2 and mRNA-1273 against BA.1, BA.5, and XBB.1.5. (sub)variants 6 months after a homologous booster: is immunogenicity equivalent?

BNT162b2 Humoral response Omicron SARS-CoV-2 Vaccine booster mRNA-1273

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
30 Aug 2024
Historique:
received: 02 02 2024
revised: 09 08 2024
accepted: 09 08 2024
medline: 9 9 2024
pubmed: 9 9 2024
entrez: 9 9 2024
Statut: epublish

Résumé

Some studies suggest that the monovalent mRNA-1273 vaccine is more effective than BNT162b2 in producing higher levels of antibodies. However, limited data are available, and the methods used are not directly comparable. Blood samples were obtained before the booster (third dose) and after 14, 90, and 180 days in two similar cohorts who received the original BNT162b2 or mRNA-1273 vaccine designed to target wild type SARS-CoV-2. The aim of our study is to compare their effectiveness by assessing the levels of binding and neutralizing antibodies specifically against each of the BA.1 variant, BA.5 variant, and the XBB.1.5 subvariant. Once the peak was reached after two weeks, a drastic decline in binding and neutralizing antibodies was observed up to 6 months after the homologous booster administration. The humoral response was however more sustained with the mRNA-1273 booster, with half-lives of 167, 55, and 48 days for binding, BA.1, and BA.5 neutralizing antibodies compared to 144, 30, and 29 days for the BNT162b2 booster, respectively. Compared to the BA.1 variant, the neutralizing capacity was significantly decreased at 6 months with the BA.5 variant (fold-decrease: 1.67 to 3.20) and the XBB.1.5. subvariant (fold-decrease: 2.86 to 5.48). Although the decrease in the humoral response was observed with both mRNA vaccines over time, a more sustained response was observed with the mRNA-1273 vaccine. Moreover, the emergence of Omicron-based variants causes a reduced neutralizing capacity, notably with the XBB.1.5. subvariant. The administration of subsequent boosters would therefore be needed to restore a sufficiently high neutralizing response.

Identifiants

pubmed: 39247272
doi: 10.1016/j.heliyon.2024.e36116
pii: S2405-8440(24)12147-0
pmc: PMC11379571
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e36116

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Julien Favresse (J)

Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, Faculty of Medicine, University of Namur, Namur, Belgium.
Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium.

Marie Tré-Hardy (M)

Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, Faculty of Medicine, University of Namur, Namur, Belgium.
Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium.
Faculty of Medicine, Université libre de Bruxelles, Brussels, Belgium.

Constant Gillot (C)

Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, Faculty of Medicine, University of Namur, Namur, Belgium.

Roberto Cupaiolo (R)

Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium.

Alain Wilmet (A)

Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium.

Ingrid Beukinga (I)

Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium.

Laurent Blairon (L)

Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium.

Jean-Louis Bayart (JL)

Department of Laboratory Medicine, Clinique St-Pierre, Ottignies, Belgium.

Mélanie Closset (M)

Department of Laboratory Medicine, Université catholique de Louvain, CHU UCL Namur, Namur, Belgium.

Loris Wauthier (L)

Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium.

Julien Cabo (J)

Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium.

Clara David (C)

Qualiblood s.a., Research and Development Department, Namur, Belgium.

Marc Elsen (M)

Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium.

Jean-Michel Dogné (JM)

Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, Faculty of Medicine, University of Namur, Namur, Belgium.

Jonathan Douxfils (J)

Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, Faculty of Medicine, University of Namur, Namur, Belgium.
Qualiblood s.a., Research and Development Department, Namur, Belgium.
Department of Biological Hematology, Centre Hospitalier Universitaire Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand, France.

Classifications MeSH